Compare HIG & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIG | KVUE |
|---|---|---|
| Founded | 1810 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Specialty Chemicals |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.8B | 33.1B |
| IPO Year | 1995 | 2023 |
| Metric | HIG | KVUE |
|---|---|---|
| Price | $138.75 | $17.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 12 |
| Target Price | ★ $144.73 | $20.00 |
| AVG Volume (30 Days) | 1.6M | ★ 33.7M |
| Earning Date | 01-29-2026 | 02-05-2026 |
| Dividend Yield | 1.73% | ★ 4.83% |
| EPS Growth | 22.54 | ★ 35.31 |
| EPS | ★ 12.22 | 0.75 |
| Revenue | ★ $27,917,000,000.00 | $15,006,000,000.00 |
| Revenue This Year | $7.59 | N/A |
| Revenue Next Year | $5.67 | $2.81 |
| P/E Ratio | ★ $11.35 | $22.99 |
| Revenue Growth | ★ 7.03 | N/A |
| 52 Week Low | $104.93 | $14.02 |
| 52 Week High | $140.50 | $25.17 |
| Indicator | HIG | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 61.73 | 57.32 |
| Support Level | $138.31 | $16.93 |
| Resistance Level | $140.50 | $17.48 |
| Average True Range (ATR) | 2.15 | 0.25 |
| MACD | 0.28 | -0.04 |
| Stochastic Oscillator | 85.08 | 57.46 |
The Hartford Insurance Group Inc. provides property and casualty insurance, group benefits, and mutual funds. The company is widely recognized for its service excellence, sustainability practices, trust, and integrity. The Company currently conducts business principally in five reportable segments including Business Insurance, Personal Insurance, Property & Casualty Other Operations, Employee Benefits, and Hartford Funds, as well as a Corporate category. The company generates a majority of its revenue from Business Insurance.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.